KR101892559B1 - 반추 동물용 항프롤락틴성 수의학적 조성물 - Google Patents

반추 동물용 항프롤락틴성 수의학적 조성물 Download PDF

Info

Publication number
KR101892559B1
KR101892559B1 KR1020177002975A KR20177002975A KR101892559B1 KR 101892559 B1 KR101892559 B1 KR 101892559B1 KR 1020177002975 A KR1020177002975 A KR 1020177002975A KR 20177002975 A KR20177002975 A KR 20177002975A KR 101892559 B1 KR101892559 B1 KR 101892559B1
Authority
KR
South Korea
Prior art keywords
treatment
ruminants
administered
veterinary composition
prolactin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020177002975A
Other languages
English (en)
Korean (ko)
Other versions
KR20170017002A (ko
Inventor
아누크 라가드
스테판 플로쉬
티에리 베르테임
Original Assignee
세바상뜨 아니말르 사
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40527505&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR101892559(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 세바상뜨 아니말르 사 filed Critical 세바상뜨 아니말르 사
Publication of KR20170017002A publication Critical patent/KR20170017002A/ko
Application granted granted Critical
Publication of KR101892559B1 publication Critical patent/KR101892559B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
KR1020177002975A 2008-10-07 2009-10-07 반추 동물용 항프롤락틴성 수의학적 조성물 Active KR101892559B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0805544A FR2936710B1 (fr) 2008-10-07 2008-10-07 Composition veterinaire antiprolactinique destinee aux ruminants
FR0805544 2008-10-07
PCT/EP2009/063004 WO2010040765A1 (fr) 2008-10-07 2009-10-07 Composition veterinaire antiprolactinique destinee aux ruminants

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020117009774A Division KR20110110091A (ko) 2008-10-07 2009-10-07 반추 동물용 항프롤락틴성 수의학적 조성물

Publications (2)

Publication Number Publication Date
KR20170017002A KR20170017002A (ko) 2017-02-14
KR101892559B1 true KR101892559B1 (ko) 2018-08-28

Family

ID=40527505

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020177002975A Active KR101892559B1 (ko) 2008-10-07 2009-10-07 반추 동물용 항프롤락틴성 수의학적 조성물
KR1020117009774A Ceased KR20110110091A (ko) 2008-10-07 2009-10-07 반추 동물용 항프롤락틴성 수의학적 조성물

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020117009774A Ceased KR20110110091A (ko) 2008-10-07 2009-10-07 반추 동물용 항프롤락틴성 수의학적 조성물

Country Status (24)

Country Link
US (2) US9730923B2 (https=)
EP (1) EP2349272B1 (https=)
JP (1) JP5955561B2 (https=)
KR (2) KR101892559B1 (https=)
CN (1) CN102215843B (https=)
AU (1) AU2009301134B2 (https=)
BR (1) BRPI0914064A2 (https=)
CA (1) CA2738875C (https=)
DK (1) DK2349272T3 (https=)
ES (1) ES2719844T3 (https=)
FR (1) FR2936710B1 (https=)
HU (2) HUE043239T2 (https=)
IL (1) IL212125B (https=)
MA (1) MA32763B1 (https=)
MX (1) MX2011003743A (https=)
NO (1) NO2019028I1 (https=)
NZ (1) NZ592288A (https=)
PL (1) PL2349272T3 (https=)
PT (1) PT2349272T (https=)
RU (1) RU2528892C2 (https=)
SI (1) SI2349272T1 (https=)
UA (1) UA103779C2 (https=)
WO (1) WO2010040765A1 (https=)
ZA (1) ZA201103273B (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2971423B1 (fr) 2011-02-15 2014-01-10 Ceva Sante Animale Composition veterinaire antiprolactinique destinee aux ruminants
EP2995297A1 (fr) * 2014-09-09 2016-03-16 Ceva Sante Animale Compositions parentérales et leurs utilisations
US20200071408A1 (en) 2016-11-29 2020-03-05 National Center Of Neurology And Psychiatry Prophylactic agent, onset-suppressing agent or therapeutic agent for progressive immune demyelinating diseases
US12459965B2 (en) 2017-10-09 2025-11-04 Compass Pathfinder Limited Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
KR20220009954A (ko) 2019-04-17 2022-01-25 컴퍼스 패쓰파인더 리미티드 신경인지 장애, 만성 통증을 치료하고 염증을 감소시키는 방법
EP4064854A1 (en) 2019-11-28 2022-10-05 Boehringer Ingelheim Vetmedica GmbH Use of sglt-2 inhibitors in the drying-off of non-human mammals
UY39022A (es) * 2020-01-27 2021-07-30 Ceva Sante Animale Composición veterinaria de anti-prolactina para rumiantes utilizada mediante administración intramamaria
AR122366A1 (es) * 2020-01-27 2022-09-07 Ceva Sante Animale Composición veterinaria para rumiantes lecheros para el tratamiento de la fiebre de la leche

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000054776A1 (en) * 1999-03-17 2000-09-21 Eugen Eigenmann Use of prolactin inhibitors for the treatment of fertility problems in animal species

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4839171A (en) * 1984-11-30 1989-06-13 Techmix, Inc. Composition for treating impaired lactation
US4939259A (en) * 1989-07-24 1990-07-03 Eli Lilly And Company 2-oxo-pyrido[2,3-g]quinoline derivatives
GB0108485D0 (en) * 2001-04-04 2001-05-23 Pfizer Ltd Combination therapy
NZ515178A (en) * 2001-11-23 2004-09-24 Agres Ltd Modulating prolactin receptors to affect a physiological response
GB0313892D0 (en) * 2003-06-16 2003-07-23 Hannah Res Inst Control of lactation
GB0314469D0 (en) 2003-06-20 2003-07-23 Phico Therapeutics Ltd Antimicrobial compositions and uses thereof
CN1762495B (zh) * 2004-09-21 2011-04-06 山东绿叶制药有限公司 含有多巴胺受体激动剂类药物的长效缓释制剂及其制备工艺
KR20070059161A (ko) * 2004-09-21 2007-06-11 산동 루예 파마슈티칼 컴파니 리미티드 도파민 수용체 효능제를 함유하는 장시간 작용 서방성 제제및 그 제조방법
EP1952813A1 (en) * 2007-02-01 2008-08-06 Ferring International Center S.A. Medicament for the treatment of endometriosis
ITTO20070479A1 (it) * 2007-07-02 2009-01-03 Ceva Vetem S P A Composizione veterinaria iniettabile ad attivita' anti-prolattinica

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000054776A1 (en) * 1999-03-17 2000-09-21 Eugen Eigenmann Use of prolactin inhibitors for the treatment of fertility problems in animal species

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Robert, E., et al. Reproductive toxicology, 1996, 10(4), 333-337*

Also Published As

Publication number Publication date
KR20170017002A (ko) 2017-02-14
CN102215843A (zh) 2011-10-12
KR20110110091A (ko) 2011-10-06
US20110245261A1 (en) 2011-10-06
PT2349272T (pt) 2019-05-13
DK2349272T3 (da) 2019-04-29
SI2349272T1 (sl) 2019-07-31
MX2011003743A (es) 2011-07-28
RU2011118366A (ru) 2012-11-20
AU2009301134B2 (en) 2013-12-05
CA2738875C (fr) 2017-11-21
EP2349272A1 (fr) 2011-08-03
EP2349272B1 (fr) 2019-01-16
ES2719844T3 (es) 2019-07-16
HK1161555A1 (en) 2012-07-27
BRPI0914064A2 (pt) 2015-11-03
HUS1900036I1 (hu) 2019-07-29
FR2936710B1 (fr) 2011-01-07
RU2528892C2 (ru) 2014-09-20
IL212125B (en) 2020-06-30
US20130203762A1 (en) 2013-08-08
ZA201103273B (en) 2012-07-25
JP5955561B2 (ja) 2016-07-20
IL212125A0 (en) 2011-06-30
NO2019028I1 (no) 2019-07-05
FR2936710A1 (fr) 2010-04-09
MA32763B1 (fr) 2011-11-01
PL2349272T3 (pl) 2019-08-30
NZ592288A (en) 2013-03-28
HUE043239T2 (hu) 2019-08-28
AU2009301134A1 (en) 2010-04-15
CN102215843B (zh) 2014-07-30
US9744158B2 (en) 2017-08-29
WO2010040765A1 (fr) 2010-04-15
CA2738875A1 (fr) 2010-04-15
US9730923B2 (en) 2017-08-15
UA103779C2 (ru) 2013-11-25
JP2012505178A (ja) 2012-03-01

Similar Documents

Publication Publication Date Title
KR101892559B1 (ko) 반추 동물용 항프롤락틴성 수의학적 조성물
EP2675527B1 (fr) Composition veterinaire antiprolactinique destinee aux ruminants comprenant la cabergoline
US20160250202A1 (en) Mast Cell Stabilizers to Prevent or Treat Laminitis
EP2424527A1 (en) Mast cell stabilizers to prevent or treat laminitis
TW202247844A (zh) 吡咯并嘧啶類化合物的用途
AU2013204272B2 (en) Veterinary Antiprolactinic Composition for Ruminants
Giussani et al. The oxytocin antagonist atosiban prevents androstenedione-induced myometrial contractions in the chronically instrumented, pregnant rhesus monkey
HK1161555B (en) Use of an antiprolactinic veterinary composition for the manufacture of a medicament
JP7624999B2 (ja) 乳房内投与によって使用される反芻動物のための獣医学抗プロラクチン組成物
RU2846098C1 (ru) Ветеринарная антипролактиновая композиция для жвачных животных, используемая путем введения в молочную железу
CN119522109A (zh) 用于钙调磷酸酶抑制剂的间歇性给药的组合物
WO2024013062A1 (en) Solid oral dosage form comprising vortioxetine and vitamin d
WO2016040342A1 (en) Early lactation administration of non-steroidal anti-inflammatory drugs to increase whole-lactation milk yield
CN118804754A (zh) 利用替拉扎德盐治疗和预防疾病的组合物和方法
WO2015075003A1 (en) Reducing pain in male animals during castration
Dogliotti et al. Hormonal Treatment of Fibrocystic Disease

Legal Events

Date Code Title Description
A107 Divisional application of patent
A201 Request for examination
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20170202

Application number text: 1020117009774

Filing date: 20110429

PA0201 Request for examination
PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20170306

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20170724

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20170306

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

X091 Application refused [patent]
AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20170724

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20170504

Comment text: Amendment to Specification, etc.

E90F Notification of reason for final refusal
PE0902 Notice of grounds for rejection

Comment text: Final Notice of Reason for Refusal

Patent event date: 20171031

Patent event code: PE09021S02D

AMND Amendment
PX0701 Decision of registration after re-examination

Patent event date: 20180525

Comment text: Decision to Grant Registration

Patent event code: PX07013S01D

Patent event date: 20171228

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20171016

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20170724

Comment text: Decision to Refuse Application

Patent event code: PX07011S01I

Patent event date: 20170504

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

X701 Decision to grant (after re-examination)
GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20180822

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20180822

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
FPAY Annual fee payment

Payment date: 20210723

Year of fee payment: 4

PR1001 Payment of annual fee

Payment date: 20210723

Start annual number: 4

End annual number: 4

FPAY Annual fee payment

Payment date: 20220722

Year of fee payment: 5

PR1001 Payment of annual fee

Payment date: 20220722

Start annual number: 5

End annual number: 5

PR1001 Payment of annual fee

Payment date: 20230802

Start annual number: 6

End annual number: 6